Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ever Fortune.AI CoROCO:6841 76 EBITDA Margin % is 17.54% as of Dec. 2025. GuruFocus rates ROCO:6841 with a GF Score™ of 76/100 and a GF Value™ of NT$218.09 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Ever Fortune.AI Co ranks better than 95.78% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ever Fortune.AI Co's EBITDA for the
three
months ended in Dec. 2025 was NT$25.0 Mil. Ever Fortune.AI Co's Revenue for the
three
months ended in Dec. 2025 was NT$142.6 Mil. Therefore, Ever Fortune.AI Co's EBITDA margin for the quarter that ended in Dec. 2025 was 17.54%.
Ever Fortune.AI Co (ROCO:6841) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ever Fortune.AI Co EBITDA Margin % Related Terms
Ever Fortune.AI Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ever Fortune.AI Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6841 vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Ever Fortune.AI Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ever Fortune.AI Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ever Fortune.AI Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ever Fortune.AI Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ever Fortune.AI Co (ROCO:6841) has a EBITDA Margin % of 17.54% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ever Fortune.AI Co and its competitors. According to the industry distribution chart, Ever Fortune.AI Co ranks #28 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 4.2%.
Is Ever Fortune.AI Co's EBITDA Margin % too high?
Ever Fortune.AI Co's current EBITDA Margin % is 17.54%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Ever Fortune.AI Co's value of 17.54% is 71.4% above this industry median. Based on the distribution chart, Ever Fortune.AI Co ranks #28 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Ever Fortune.AI Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ever Fortune.AI Co's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Ever Fortune.AI Co ranks #28 out of 664 companies for EBITDA Margin %. This places Ever Fortune.AI Co in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.24. Ever Fortune.AI Co's value of 17.54% is 71.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ever Fortune.AI Co's current EBITDA Margin % of 17.54% is 71.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ever Fortune.AI Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ever Fortune.AI Co's current EBITDA Margin % is 17.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ever Fortune.AI Co stock overvalued right now?
Based on GuruFocus' analysis, Ever Fortune.AI Co (ROCO:6841) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$218.09, compared to a current price of NT$63.50 — trading 70.9% below its estimated fair value. The current EBITDA Margin % is 17.54% and 71.4% above the Healthcare Providers & Services industry median of 10.24. Ever Fortune.AI Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ever Fortune.AI Co (ROCO:6841), the current EBITDA Margin % is 17.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ever Fortune.AI Co (ROCO:6841) Overvalued in 2026?
Based on GuruFocus' analysis, Ever Fortune.AI Co stock appears to be undervalued.
The current stock price of NT$63.50 is trading 70.9% below its estimated GF Value™ of NT$218.09.
GuruFocus considers Ever Fortune.AI Co to be Significantly Undervalued.
Key valuation signals for ROCO:6841:
EBITDA Margin %: 17.54%
GF Value™: NT$218.09 vs. price of NT$63.50 (70.9% below fair value)
Industry Position: 71.4% above the Healthcare Providers & Services median (#28 of 664)
No single metric tells the full story. See the ROCO:6841 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ever Fortune.AI Co Ltd is composed of establishing a cloud medical platform based on medical Big data, and to provide customized medical artificial intelligence solutions and services in various biomedical fields. The results both provide a professional second opinion for doctors and assist clinical doctors in making a medical diagnosis, which in turn raises the speed, accuracy, and efficiency of medical decisions. The products of the company include: Medical Artificial Intelligence, Cloud Biomedical Platform, and Medical Big Data. Its segments are: Medical AI Department; Biotechnology Department; and Others, where maximum revenue is derived from Biotechnology Department segment. Geographically, it operates in Taiwan, U.S.A., and Vietnam, of which maximum revenue is generated from Taiwan.
76GF Score
Get the complete analysis for ROCO:6841
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6841 has been successfully added to your 
